Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 19/20 | 0.80 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3634735 | 0.86 | QPCT (0.80) | QPCTNPC1RAB9A | |
| SCHEMBL6814644 | 0.86 | QPCT (0.59) | QPCTNPC1RAB9A | |
| SCHEMBL3630011 | 0.86 | QPCT (0.80) | QPCT | |
| SCHEMBL3630017 | 0.86 | QPCT (0.80) | QPCT | |
| SCHEMBL7643121 | 0.84 | QPCT (0.58) | QPCTNPC1RAB9A | |
| SCHEMBL3667914 | 0.82 | QPCT (0.58) | QPCTNPC1RAB9A | |
| SCHEMBL3629554 | 0.82 | QPCT (0.81) | QPCTNPC1RAB9A | |
| SCHEMBL6814638 | 0.81 | QPCT (0.54) | QPCTNPC1RAB9A | |
| SCHEMBL3633563 | 0.81 | QPCT (0.85) | QPCT | |
| SCHEMBL5760871 | 0.80 | QPCT (0.51) | QPCT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9656991-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2017-05-23 | — | — | US | claimed |
| EP-2865670-B1 | Thiourea derivatives as glutaminyl cyclase inhibitors | PROBIODRUG AG (DE) | 2017-01-11 | — | — | EP | claimed |
| EP-2865670-A1 | Thiourea derivatives as glutaminyl cyclase inhibitors | Probiodrug AG (DE) | 2015-04-29 | — | — | EP | claimed |
| US-20080286231-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2008-11-20 | — | — | US | claimed |
| US-9656991-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2017-05-23 | — | — | US | disclosed |
| US-9656991-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2017-05-23 | — | — | US | disclosed |
| US-9656991-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2017-05-23 | — | — | US | disclosed |
| EP-2865670-B1 | Thiourea derivatives as glutaminyl cyclase inhibitors | PROBIODRUG AG (DE) | 2017-01-11 | — | — | EP | disclosed |
| EP-2865670-B1 | Thiourea derivatives as glutaminyl cyclase inhibitors | PROBIODRUG AG (DE) | 2017-01-11 | — | — | EP | disclosed |
| EP-2865670-A1 | Thiourea derivatives as glutaminyl cyclase inhibitors | Probiodrug AG (DE) | 2015-04-29 | — | — | EP | disclosed |
| EP-2865670-A1 | Thiourea derivatives as glutaminyl cyclase inhibitors | Probiodrug AG (DE) | 2015-04-29 | — | — | EP | disclosed |
| EP-2142514-A1 | THIOUREA DERIVATIVES AS GLUTAMINYL CYCLASE INHIBITORS | Probiodrug AG (DE) | 2010-01-13 | — | — | EP | disclosed |
| US-20080286231-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2008-11-20 | — | — | US | disclosed |
| US-20080286231-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2008-11-20 | — | — | US | disclosed |
| US-20080286231-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2008-11-20 | — | — | US | disclosed |
| WO-2008128985-A1 | THIOUREA DERIVATIVES AS GLUTAMINYL CYCLASE INHIBITORS | PROBIODRUG AG (DE) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008128985-A1 | THIOUREA DERIVATIVES AS GLUTAMINYL CYCLASE INHIBITORS | PROBIODRUG AG (DE) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080286231-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | GLS, GLS2, QPCT | QPCT 3/4885NPC1 3047/4885RAB9A 725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.